Trial results
$AUTL — obe-cel
Autolus Therapeutics plc (AUTL) obe-cel: trial results in Pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL), 2027.
The catalyst
"Our Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ("r/r B-ALL") is on track and data are expected to be reported at the end of 2027."
— Autolus Therapeutics plc, 10-Q filed 2026-11-10 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
AUTL-OBECEL-2026- Company
- Autolus Therapeutics plc
- Kind
- Trial results
- Indication
- Pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)
- Window
- 2027-01-01 – 2027-12-31
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.